Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
2'-5'-Oligoadenylate synthetase like 2, pseudogene (OASL2P) is classified as a pseudogene, rather than an active protein-coding gene[3]. Pseudogenes arise from gene duplications or retrotransposition events and typically do not encode functional proteins because of mutations that disrupt their coding sequence or regulatory regions. OASL2P is predicted based on sequence similarity with other oligoadenylate synthetases but lacks demonstrable functional protein product. Thus, it is not a therapeutic target, is not associated with known biological pathways or disease mechanisms, and does not interact with any known drugs. The functional, related OAS proteins (such as OAS1, OAS2, OAS3, and OASL) are interferon-induced antiviral enzymes essential for innate immunity, but OASL2P itself does not contribute to these activities[1][2][4][5][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 2'-5'-Oligoadenylate synthetase like 2, pseudogene (OASL2P).